aleptolan 4 mg apvalkotās tabletes
g.l. pharma gmbh, austria - risperidons - apvalkotā tablete - 4 mg
aleptolan 3 mg apvalkotās tabletes
g.l. pharma gmbh, austria - risperidons - apvalkotā tablete - 3 mg
aleptolan 2 mg apvalkotās tabletes
g.l. pharma gmbh, austria - risperidons - apvalkotā tablete - 2 mg
aivareta 0,03 mg/3 mg apvalkotās tabletes
sandoz d.d., slovenia - ethinylestradiolum, drospirenonum - apvalkotā tablete - 0,03 mg/3 mg
ambrolan 30 mg tabletes
g.l. pharma gmbh, austria - ambroksola hidrohlorīds - tablete - 30 mg
stimufend
fresenius kabi deutschland gmbh - pegfilgrastim - neitropēnija - imunitātes stimulatori, , koloniju stimulējošā faktori - ilguma samazināšanās neutropenia un saslimstība ar pieaugušiem pacientiem drudža neutropenia ārstēti ar citotoksiskas ķīmijterapijas ļaundabīgo audzēju (izņemot myeloid hroniskas leikēmijas un myelodysplastic sindromi).
foscarnet sodium tillomed 24 mg/ml šķīdums infūzijām
tillomed pharma gmbh, germany - foscarnetum natricum hexahydricum - Šķīdums infūzijām - 24 mg/ml
celdoxome pegylated liposomal
yes pharmaceutical development services gmbh - doksorubicīna hidrohlorīds - breast neoplasms; ovarian neoplasms; multiple myeloma; sarcoma, kaposi - antineoplastiski līdzekļi - celdoxome pegylated liposomal is indicated in adults:as monotherapy for patients with metastatic breast cancer, where there is an increased cardiac risk. or treatment of advanced ovarian cancer in women who have failed a first-line platinum-based chemotherapy regimen. in combination with bortezomib for the treatment of progressive multiple myeloma in patients who have received at least one prior therapy and who have already undergone or are unsuitable for bone marrow transplant. for treatment of aids-related kaposi’s sarcoma (ks) in patients with low cd4 counts (< 200 cd4 lymphocytes/mm3) and extensive mucocutaneous or visceral disease. celdoxome pegylated liposomal may be used as first-line systemic chemotherapy, or as second line chemotherapy in aids-ks patients with disease that has progressed with, or in patients intolerant to, prior combination systemic chemotherapy comprising at least two of the following agents: a vinca alkaloid, bleomycin and standard doxorubicin (or other anthracycline).
atirabo 60 mg apvalkotās tabletes
tad pharma gmbh, germany - ticagrelorum - apvalkotā tablete - 60 mg
atirabo 90 mg apvalkotās tabletes
tad pharma gmbh, germany - ticagrelorum - apvalkotā tablete - 90 mg